Glaxosmithkline Share News (GSK)

GSK to restrict US use of cancer drug Zejula to some populations

(Alliance News) - GSK PLC on Friday said it will restrict the use of its niraparib, sold under the brand name Zejula, to patients in the US.

Second-line use of GSK cancer drug restricted

(Sharecast News) - The second-line application of a GSK cancer treatment will be limited following a request by the US regulators, the drugs giant said on Friday.

Much of biopharma industry yet to set climate impact targets - report

LONDON, Nov 9 (Reuters) - Much of the global pharmaceutical and biotech industry has yet to set any targets for reducing carbon emissions in line with the Paris Agreement, a new analysis has found, despite the biggest companies in the sector leading the way.

LONDON MARKET CLOSE: Cooling US inflation triggers risk-on rally

(Alliance News) - Equities in Europe were celebrating a cooler-than-expected US CPI print on Thursday, which gave rise to hopes that peak inflation in the US has passed.

Sanofi, GSK score late win with EU COVID booster approval

Nov 10 (Reuters) - Sanofi said on Thursday it won European Union approval for its COVID-19 vaccine booster, jointly made with British partner GSK, after a drawn-out development effort that saw the pair fall behind now-dominant vaccine suppliers.

UK dividends calendar - next 7 days

Much of biopharma industry yet to set any climate impact targets - report

LONDON, Nov 9 (Reuters) - Much of the global pharmaceutical and biotech industry has yet to set any targets for reducing carbon emissions in line with the Paris Agreement, a new analysis has found, despite the biggest companies in the sector leading the way.

Cancer drugmaker Clovis flags possible bankruptcy

Nov 9 (Reuters) - U.S. drugmaker Clovis Oncology said on Wednesday it was likely to file for bankruptcy "in the very near term", as the company struggles to sell its cancer drug Rubraca.

LONDON BROKER RATINGS: Peel cuts Persimmon; Liberum raises Hammerson

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

FTSE 100 lags European peers as GSK, stronger pound weigh

FTSE 100 down 0.5%, FTSE 250 adds 1.2%

*

European shares at seven-week peak as travel stocks shine

Flutter, Ryanair lead travel stocks higher

*

LONDON MARKET CLOSE: FTSE 100 lags behind European counterparts

(Alliance News) - Stock prices in London came to a mixed closed on Monday, as the FTSE 100 underperformed its European peers, while the domestically-focused FTSE 250 index saw a stronger day.

U.S. Supreme Court rejects Bristol Myers cancer-drug patent fight with Gilead

WASHINGTON, Nov 7 (Reuters) - The U.S. Supreme Court on Monday rebuffed a bid by Bristol Myers Squibb Co's Juno Therapeutics Inc to reinstate a $1.2 billion award it won in its patent fight with Gilead Sciences Inc subsidiary Kite Pharma Inc over a lymphoma drug.

U.S. Supreme Court rejects Bristol Myers cancer-drug patent fight with Gilead

WASHINGTON, Nov 7 (Reuters) - The U.S. Supreme Court on Monday rebuffed a bid by Bristol Myers Squibb Co's Juno Therapeutics Inc to reinstate a $1.2 billion award it won in its patent fight with Gilead Sciences Inc subsidiary Kite Pharma Inc over a lymphoma drug.

LONDON MARKET MIDDAY: FTSE 100 treads water but European shares rise

(Alliance News) - The FTSE 100 stood out on Monday, but for the wrong reason, as share price falls for some of its largest constituents meant the index London large-caps underperformed versus the mid-cap FTSE 250 and European indices.